AstraZeneca Drops 1st Circ. Row Over Nexium Class Cert.
AstraZeneca AB and three generic-drug producers asked the First Circuit on Wednesday to dismiss their bid to nix class certification in a suit over alleged pay-for-delay deals regarding the heartburn drug...To view the full article, register now.
Already a subscriber? Click here to view full article